ArticleScientific reports2025
Pharmacodynamic interactions among meropenem ciprofloxacin and gentamicin in an in-vitro model.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Meropenem, gentamicin and ciprofloxacin are often used together as empiric broad-spectrum therapy in different combinations. Recent regulations regarding the use of quinolones mean that greater justification is required when using this component of the combination. An understanding of the pharmacodynamic interactions of the different components of this combination is currently lacking-this could provide insight into the necessity of using the different agents. We aimed to study two- and three-way pharmacodynamic drug-drug interaction between meropenem, gentamicin and ciprofloxacin against Escherichia coli. Static time kill curve experiments were conducted with Escherichia coli (NCTC® 12,241) at 0.25-16 × MIC for a duration of 24 h with samples being collected at 0, 2, 4, 6, 8, and 24 h. Meropenem, gentamicin and ciprofloxacin were tested alone and in two- and three-way combinations. Bacterial load time series data were enumerated on Mueller Hinton agar and colony forming unit data were modelled using nonlinear mixed-effects models in the nlmixr package. Meropenem, gentamicin and ciprofloxacin two- and three-way combinations prevented regrowth, but regrowth was seen when these agents were studied alone. Gentamicin and meropenem were synergistic in decreasing ciprofloxacin IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.